Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2025-10-01 Proxy Solicitation & In…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Zmieniona treść ogłoszenia o zwołaniu NWZ Pure Biologics S.A. na dzień 21.10.2025
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice ('Ogłoszenie') from the Board of Directors of Pure Biologics S.A. regarding the convening of an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie). It details the agenda, registration procedures, voting rights, and proxy information for shareholders. This is a standard proxy solicitation and information statement provided to shareholders to facilitate participation in a corporate meeting.
2025-10-01 Polish
Zmiana w porządku obrad Nadzwyczajnego Walnego Zgromadzenia Pure Biologics S.A. wraz z treścią projektów uchwał - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Pure Biologics S.A. announcing a request from a shareholder to expand the agenda of an Extraordinary General Meeting. It provides the updated agenda and draft resolutions as attachments. Since this is a formal notification regarding meeting procedures and documentation, and it does not constitute the meeting materials themselves (but rather an announcement of their update), it falls under the category of general regulatory announcements.
2025-10-01 Polish
Raport niezależnego biegłego rewidenta z badania sprawozdania finansowego Pure Biologics S.A. za okres 1.01.2025-30.06.2025
Audit Report / Information Classification · 100% confidence The document is a 'Report of an Independent Auditor' (Raport niezależnego biegłego rewidenta) regarding the review of interim condensed financial statements for the 6-month period ending June 30, 2025. It explicitly details the scope of the review, the auditor's conclusion, and includes a section on 'Material uncertainty related to going concern'. As this is a standalone audit/review report and not the full interim financial report itself, it falls under the 'Audit Report / Information' category. H1 2025
2025-09-30 Polish
Skrócone śródroczne sprawozdanie finansowe Pure Biologics S.A. za okres 1.01.2025-30.06.2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Śródroczne skrócone sprawozdanie finansowe' (Interim Condensed Financial Statement) for the period 01.01.2025 to 30.06.2025. It contains comprehensive financial statements, including the statement of profit or loss, statement of financial position, cash flow statement, and notes to the financial statements. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-30 Polish
Jednostkowy raport półroczny Pure Biologics S.A. za okres 1.01.2025-30.06.2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Jednostkowy Raport Półroczny' (Standalone Semi-Annual Report) for the period ending 30.06.2025. It contains a comprehensive table of contents covering financial statements, an auditor's report, and a detailed management report (Sprawozdanie z działalności). As it is a full interim financial report containing substantive financial data and analysis, it fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-30 Polish
Treść projektów uchwał NWZ Pure Biologics S.A. zwołanego na dzień 21.10.2025
AGM Information Classification · 100% confidence The document contains the text of resolutions passed by the Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie) of Pure Biologics S.A. It details specific corporate actions, including the election of a chairman, adoption of the agenda, and a significant resolution regarding a capital increase through the issuance of new shares (Series P2) with pre-emptive rights. These materials are typical of proxy solicitation or information statements provided to shareholders for voting purposes at a general meeting.
2025-09-24 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.